Oncotelic's AI Platform Integrates 28M Abstracts to Transform Drug Discovery

Artificial intelligence is no longer a buzzword in the life sciences; it is rapidly becoming the defining infrastructure layer of modern drug development. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool. The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts into its PDAOAI platform, dramatically expanding the platform's knowledge base and its potential to identify novel drug targets and repurpose existing compounds. This move positions Oncotelic to compete with much larger players by leveraging AI to accelerate drug development while reducing costs.

The broader market context makes Oncotelic's strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion. Oncotelic's central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs; it is intended to serve as a comprehensive engine for drug discovery and repurposing across multiple therapeutic areas. By integrating 28 million scientific abstracts, the platform can now analyze vast amounts of literature to uncover hidden connections between drugs, diseases, and biological pathways, potentially identifying treatments for rare and neglected diseases that big pharma often overlooks.

Oncotelic's approach highlights a growing trend where small biotech companies can out-innovate large pharmaceutical firms by focusing on niche applications of AI. While big pharma often relies on massive data sets and expensive computing infrastructure, Oncotelic's platform is designed to be agile and focused, enabling rapid hypothesis generation and validation. This could lead to faster clinical trials and more targeted therapies, ultimately benefiting patients who lack effective treatment options. For investors, Oncotelic represents a high-risk, high-reward opportunity in the rapidly evolving AI-drug discovery space, with the potential to disrupt traditional pharmaceutical R&D models.